BPC-157 + TB-500 Blend: Two Literatures in One Vial
Our BPC-157 + TB-500 blend puts two research compounds in one vial. It would be easy to write about it as if it were one thing. It is not. BPC-157 has its own literature. TB-500 has its own, much smaller, literature. Nobody has published research on the two together. This post explains what that means, summarises each compound side by side, and shows how a two-component lot is tested so you know exactly what you are looking at.
What is in the vial
The blend is a single freeze-dried vial containing BPC-157 and TB-500 in equal amounts. That is the whole recipe. There is no third ingredient. The measured content of each component for a given lot is stated on that lot's certificate of analysis.
What "studied" means, and why a blend has none
A study changes one thing and measures what happens. In a typical BPC-157 animal study, one group of animals receives the peptide and a matched group does not, and the two are compared. The result tells you about BPC-157. It tells you nothing about BPC-157 in the presence of a second compound.
To learn about a combination you need experiments designed for the combination: groups for each compound alone, a group for both together, and a control. That is more work, and for this pair nobody has published it. So the correct statement about the blend is simple. The two compounds are studied separately, and what we can summarise is each component, not any combined effect.
We think this is worth saying plainly, because a blend name can make two separate bodies of evidence look like one.
What the blend name does not mean
A quick list, because the name carries more weight online than it should.
- It is not a nickname for a single compound. There are two molecules in the vial, with two different structures and two different histories.
- It is not a sign that the pair has been tested together. No such study exists in the references we work from.
- It is not a sign of a shared mechanism. The pathways proposed for BPC-157 and the actin biology behind thymosin beta-4 come from different papers and different fields.
What the name does mean is simple: two research compounds, one container, equal amounts, and a certificate that confirms both.
Literature one: BPC-157
BPC-157 is a synthetic 15-amino-acid peptide whose sequence was originally described from a protein in gastric juice. Its research areas are tendon, ligament and muscle injury models, bone healing in animals, gastrointestinal mucosal protection models, and angiogenesis and nitric oxide signaling. Proposed mechanisms, all from cell and animal work, include VEGFR2 and Akt-eNOS signaling, ERK1/2, FAK-paxillin and growth hormone receptor expression in fibroblasts (McGuire et al., 2025).
A 2025 systematic review included 36 studies, of which 35 were preclinical (Vasireddi et al., 2025). Human data are limited to three small pilot reports, including one on intravenous infusion in two adults (Lee and Burgess, 2025). Most of the preclinical papers come from one group in Zagreb. WADA lists BPC-157 under S0, non-approved substances.
Literature two: TB-500
TB-500 is a trade name. Analytical studies of TB-500 products identified an N-acetylated seven-residue fragment of thymosin beta-4, residues 17 to 23, written Ac-LKKTETQ (Esposito et al., 2012). That stretch is the central actin-binding site of thymosin beta-4, a 43-amino-acid actin-sequestering protein, and it has been associated with cell migration and angiogenesis in laboratory studies (Sosne et al., 2010).
Most TB-500-specific papers are about anti-doping detection and metabolism (Ho et al., 2012). A 2024 study measured the fragment and its metabolites in rats and screened them in a cell-based wound-healing assay, noting that TB-500's own biological effects had not previously been documented (Rahaman et al., 2024). Whether the fragment reproduces the parent protein's effects is not established. WADA prohibits thymosin beta-4 and its derivatives, naming TB-500, under S2.
Side by side
| Question | BPC-157 | TB-500 |
|---|---|---|
| What is it? | Synthetic 15-residue peptide | Acetylated 7-residue fragment of thymosin beta-4 |
| Main models | Rodent tendon, bone and gut models; cell signaling | Anti-doping analytics; cell migration assays; one rat tendon study |
| Human data | Three small pilot reports | None found |
| Mechanism | Proposed, not established | Not established for the fragment |
| Who publishes | Mostly one group | Mostly analytical and anti-doping labs |
| WADA | S0, non-approved substances | S2, thymosin beta-4 and derivatives |
| Combined research | None published | None published |
Two columns, two literatures, and a last row that reads the same on both sides. That table is the honest summary of the blend.
Reading a blend certificate
A single-compound certificate answers two questions: is it the right molecule, and how pure is it? A blend certificate has to answer those questions for each compound, and then one more.
Two identities
Mass spectrometry (MS) must show both expected masses: the 15-residue BPC-157 and the much smaller acetylated fragment. The two are far apart in mass, so they are easy to tell apart. Both should be present and neither should be missing.
Two main peaks
On the HPLC trace a blend lot shows two principal peaks rather than one. The certificate reports the measured purity of the material and the identity of each peak. We do not quote one figure for every lot. Each lot's certificate states its own numbers.
Content per component
Because the two are present in equal amounts, the certificate should also tell you how much of each is in the vial. That is what makes "equal amounts" a measured statement rather than a label claim.
As always, the lot number on the certificate should match the vial.
Storage
The blend is supplied as a freeze-dried powder. Keep sealed vials cool, dry and out of direct light, and let a cold vial reach room temperature before opening. These are storage notes for the laboratory, not instructions for use.
Single vials or the blend?
This is a research-design question, and the answer depends on the experiment. Single vials of BPC-157 and TB-500 let a laboratory vary one compound at a time, which is how the published studies were done. The blend gives a fixed ratio in one container, which suits work where the two are always handled together. Neither choice changes the evidence. The literature is per compound either way.
Frequently asked questions
Has the BPC-157 and TB-500 combination been studied?
No. Our research summary found no published study of the two together. Each compound has its own literature, and this article summarises them separately for that reason.
What does "equal amounts" mean on the blend?
The vial contains the same amount of BPC-157 as TB-500. The measured content of each component for a specific lot is stated on that lot's certificate of analysis.
Why are the two compounds in different WADA sections?
BPC-157 is listed under S0, non-approved substances. TB-500 falls under S2 as a derivative of thymosin beta-4. Both are prohibited, but under different parts of the list's structure.
How does a blend certificate differ from a single-compound certificate?
It confirms two identities by mass spectrometry, shows two main HPLC peaks, and reports the content of each component, in addition to the lot number and test date.
See it in the catalogue: BPC-157 + TB-500 blend.
For laboratory research use only. Products sold by Amino Party Peptides are not drugs, foods, supplements or cosmetics and are not for human or veterinary use. This article summarises published literature; it is not medical advice and not a usage guide.